Benzinga - by Zacks, Benzinga Contributor.
Wall Street analysts forecast that Merck (NYSE: MRK) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-over-year increase of 43.6%. It is anticipated that revenues will amount to $15.34 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.
Over the last 30 days, there has been an upward revision of 7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Merck metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Reblozyl' at $68.77 million. The estimate indicates a change of +59.9% from the prior-year quarter.
The consensus estimate for 'Sales- Vaccines- Pneumovax' stands at $70.63 million. The estimate points to a change of -26.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- Vaccines- ProQuar/M-M-R II/Varivax' of $544.16 million. The estimate suggests a change of +3.1% year over year.
The consensus among analysts is that 'Sales- Alliance revenue- Lenvima' will reach $265.43 million. The estimate indicates a year-over-year change of +14.4%.
Analysts predict that the 'Sales- Hospital Acute Care- Bridion - U.S.' will reach $301.76 million. The estimate indicates a change of +9.3% from the prior-year quarter.
Analysts' assessment points toward 'Product sales- Other revenues - International' reaching $198.07 million. The estimate suggests a change of -7.5% year over year.
Based on the collective assessment of analysts, 'Sales- Oncology- Keytruda - U.S.' should arrive at $4.12 billion. The estimate points to a change of +18.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Hospital Acute Care- Bridion - International' will likely reach $124.70 million. The estimate indicates a year-over-year change of -40.6%.
Analysts expect 'Sales- Animal health - International' to come in at $1.05 billion. The estimate indicates a change of +4.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Sales- Animal health - U.S.' should come in at $495.47 million. The estimate indicates a year-over-year change of +2.8%.
Analysts forecast 'Sales- Vaccines- Pneumovax - International' to reach $42.22 million. The estimate points to a change of -24.6% from the year-ago quarter.
It is projected by analysts that the 'Sales- Vaccines- Pneumovax - U.S.' will reach $28.41 million. The estimate points to a change of -29% from the year-ago quarter.
To read this article on Zacks.com click here.